Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals has a 12 month low of $284.19 and a 12 month high of $495.55. The stock’s 50 day moving average is $312.56 and its 200-day moving average is $362.08. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a market ca…

Twin Capital Management Inc. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 4th quarter, HoldingsChannel reports. The firm bought 2,208 shares of the biopharmaceutical company’s stock, valued at approximately $878,000.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 1, Morgan Stanley bumped up its price goal on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $370 from $360. It maintained an Equal Weight rating on the stock.

• KTOS, PLTR, and ALNY appear attractive bets despite high P/E ratios. • They offer more than 40% upside over the next 12 months. Using the TipRanks Highest P/E Ratio Stocks tool, we identified three companies with high price-to-earnings (P/E) ratios and more than 40% upside potential over ...

On simple P/E math, Alnylam looks expensive. The stock trades around 73.4x earnings, compared with a fair ratio estimate of 29.8x, the US Biotechs average of 17.8x and a 30.4x peer average.